<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540720</url>
  </required_header>
  <id_info>
    <org_study_id>Zhai</org_study_id>
    <nct_id>NCT02540720</nct_id>
  </id_info>
  <brief_title>The Research of Standard Diagnosis and Treatment for Severe HSP in Children</brief_title>
  <official_title>The Research of Standard Diagnosis and Treatment for Severe Henoch-Schonlein Purpura in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to evaluate the efficacy and safety of various measures in the
      treatment of severe HSP in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Henoch-Schonlein purpura (HSP) is a systemic vasculitis affecting small vessels with
      immunoglobulin A (IgA)-dominant immune deposits. The clinical manifestations of severe HSP
      vary from massive hemorrhage and necrosis of the skin to severe gastrointestinal symptoms.
      The course of the disease would encounter delay and relapse. To some extent, the traditional
      therapy alleviate the clinical symptoms, but fail to timely clear up the immune depositions,
      causing the damage to the kidney.

      In the study, the patients will be given dexamethasone 0.5mg/kg/d, then be randomised to
      receive either gamma globulin i.v. or hemoperfusion if the disease can't be controlled with
      steroid treatment for more than two days.

      The investigators will explore the biological markers and compare the efficacy and safety of
      both measures in the treatment of serve HSP in children. The purpose of the study is to
      optimize the treatment of severe HSP for children with different ages.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Symptoms of Digestive Tract</measure>
    <time_frame>2 weeks</time_frame>
    <description>The stomachache and other symptoms of digestive tract disappear</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Symptoms of Joint System</measure>
    <time_frame>2 weeks</time_frame>
    <description>The arthralgia disappears</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Skin Rash</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Skin Rash disappears</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>2 weeks</time_frame>
    <description>There is no damage in kidney.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Henoch-Schoenlein Purpura</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 0.5mg/kg.d i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone &amp; gamma globulin Dexamethasone 0.5mg/kg.d i.v. &amp; gamma globulin i.v. qd*3d, and the total dose is 2g/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone &amp; hemoperfusion Dexamethasone 0.5mg/kg.d i.v &amp; hemoperfusion should be given at least three times in five days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma globulin</intervention_name>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemoperfusion</intervention_name>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe HSP: could not be controlled with dexamethasone 0.5mg/kg/d or the total dose
             above 20mg/d for more than two days

        Exclusion Criteria:

          -  The children with congenital diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aihua Zhang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Nanjing children's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aihua Zhang, M.D.</last_name>
    <phone>+8618951769017</phone>
    <email>bszah@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yimei Wu</last_name>
    <phone>+8615951757930</phone>
    <email>wym891203@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing Children's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aihua Zhang, M.D.</last_name>
      <phone>+8618951769017</phone>
      <email>bszah@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Aihua Zhang</investigator_full_name>
    <investigator_title>Hospital vice president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Schoenlein-Henoch</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

